# Marius Nacht

> Marius Nacht is a Series A investor at aMoon Fund backing Artificial Intelligence. See 34 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [aMoon Fund](https://shizune.co/investors/profile/amoon)
- Location: Tel Aviv-yafo, Israel
- Total investments: 34
- Last investment: Sep 2024
- Lead investor: 44%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/marius-nacht/?originalSubdomain=il

Marius Nacht is a Series A investor at aMoon Fund in Tel Aviv-yafo focused on Artificial Intelligence and Machine Learning. Marius Nacht, one of Check Point’s founders, has served as Chairman of our board of directors since 2015. Nacht has also served as one of our directors since we were incorporated in 1993. From 1999 through 2005, Nacht held Senior Vice President roles at Check Point. Nacht earned a B.S. (cum laude) in Physics and Mathematics from the HebrewUniversity of Jerusalem in 1983, and an M.S. in Electrical Engineering and Communication Systems from Tel Aviv University in 1987.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $3M–$120M |
| Series A | $5M–$23M |
| Series B | $8M–$83M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Artificial Intelligence | 10 | 29% |
| Machine Learning | 7 | 21% |
| Health Care | 6 | 18% |
| Cyber Security | 5 | 15% |
| Medical | 4 | 12% |

64 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 13 | 38% |
| Series B | 6 | 18% |
| Seed | 5 | 15% |
| Funding Round | 3 | 9% |
| Venture - Series Unknown | 3 | 9% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Israel | 14 | 41% |
| United States | 9 | 26% |
| Germany | 1 | 3% |
| Switzerland | 1 | 3% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CPTx | CPTx develops single-stranded DNA products to neutralize viruses and address infectious diseases. | $29M | Venture - Series Unknown | Sep 12, 2024 |  |
| WaveBL | WaveBL is a digital platform using proprietary blockchain technology to transfer electronically trade documents. The WaveBL solution enables the instant, encrypted, and authenticated transfer of electronic Bills of Lading and related trade documents. The platform complies with universal processes and regulations in use. The platform is designed tomeet the needs of all parties involved in trade, including shipping companies, agents, brokers, and banks. WaveBL has strong alliances with leading companies in global trade to drive faster digitalization and adoption. | $37M | Series B | Jun 06, 2023 |  |
| Wisdo Health | Wisdo is an AI-powered Social Health platform harnessing the power of data and meaningful connections to improve health. | $5M | Series A | Jan 05, 2023 |  |
| CommonGround-AI | CommonGround-AI provides a new 3D video platform. | $25M | Series A | Nov 30, 2022 |  |
| Ultima Genomics | Ultima Genomics is unleashing the power of genomics at scale. Ultima Genomics drives the scale of genomic information to enable unprecedented advances in biology and improvements in human health. | $600M | Venture - Series Unknown | May 31, 2022 |  |
| BioGenCell | BioGenCell designs cellular therapies that treat blood flow problems in the limbs, a side effect of diabetes and heart disease. Its technology creates autologous cells, derived from the patients themselves, to repair themselves. Its lead product, BC1, uses the company's technology to treat blood vessel insufficiency that can cause multipleorgan failure in diabetic patients. Derived from the patient's own adult stem cells, its easy-to-use and cost-effective therapies can regenerate damaged tissues, with the eventual goal of treating a wide range of degenerative diseases including diabetes, heart failure, stroke, blindness, cancer, and immunological diseases. Its patented technology platform provides a comprehensive solution for most aspects of cellular therapy and supports rapid manufacturing and long-term storage (bio-banking) of therapeutic cellular products for use in patient treatment. | $16M | Seed | May 09, 2022 |  |
| WINT | WINT - Water Intelligence developing advanced solutions for smart water management and control. The company detects and stops leaks at the source using Artificial Intelligence. It is used in commercial and industrial facilities, offices, homes, and apartments. It also prevents water damage caused by leaks, broken pipes or malfunctioning watersystems.WINT customers gain deep insights about their water use to identify water waste and reduce consumption by 25%. They manage water and detect leaks using artificial intelligence and pattern matching technologies, combining high accuracy metering with advanced data analytics. WINT solutions protect global real estate portfolios and homes by revealing leaks and identifying water savings opportunities.WINT was founded in 2011 and is headquartered in New York, USA. | $15M | Series B | Jan 11, 2022 |  |
| GrayMatters Health | GrayMatters Health delivers beyond the pill digital therapeutics for mental disorders through self-neuromodulation of brain processes. | $10M | Series A | Jan 11, 2022 |  |
| 1E Therapeutics | 1E Therapeutics is a breakthrough, drug development company creating RNA-targeting therapeutics based on a proprietary drug design platform. | $120M | Seed | Dec 08, 2021 |  |
| TriEye | TriEye is the pioneer of mass-market, CMOS-based Short-Wave infrared (SWIR) sensing solutions. Based on advanced academic research, TriEye’s breakthrough and proprietary technology enables cost-effective, high-resolution image data and depth perception in all weather and lighting conditions. Founded in 2017, the company’s cutting-edge technologyallows perception systems to operate and deliver reliable image data and actionable information, while reducing expenditure by up to 1,000x the existing industry rates. | $74M | Series B | Nov 10, 2021 |  |

10 of 34 investments shown.

## Co-investors
- [Grove Ventures](https://shizune.co/investors/profile/grove-ventures) — VC Fund, 7 deals together
- [Intel Capital](https://shizune.co/investors/profile/intel-capital) — VC Fund, 5 deals together
- [ZIM Integrated Shipping Services](https://shizune.co/investors/profile/zim-integrated-shipping-service-ltd) — VC Fund, 5 deals together
- [StageOne Ventures](https://shizune.co/investors/profile/stageone-ventures) — VC Fund, 4 deals together
- [Allied Group Investments](https://shizune.co/investors/profile/allied-group-investments) — VC Fund, 2 deals together
- [aMoon Fund](https://shizune.co/investors/profile/amoon) — VC Fund, 2 deals together

## About aMoon Fund

VC Fund · Ra'anana, Israel

aMoon is a leading healthtech & life sciences venture fund founded by Marius Nacht and Dr. Yair Schindel. Their team is passionate about building successful businesses and helping biopharma, digital health and medical technology companies realize their potential. They partner with management teams who use technology and cutting-edge science toaccelerate cures for the world’s most life-threatening conditions and those providing solutions for global healthcare’s biggest cost drivers.

5 contacts available at aMoon Fund.

| Name | Title | Profile |
| --- | --- | --- |
| Moshe Mor | General Partner | https://shizune.co/investors/profile/moshe-mor |
| Gur Roshwalb | Managing Director | https://shizune.co/investors/profile/gur-roshwalb |
| Itay Bengad | Executive in Residence | https://shizune.co/investors/profile/itay-bengad-endovitech |
| Marius Nacht | Founder & Anchor Investor | https://shizune.co/investors/profile/marius-nacht |
| Michal Goren Miller | Chief Legal Counsel & Chief Compliance Officer | https://shizune.co/investors/profile/michal-goren-miller |

## Similar investors

### Similar industry
- [SV Angel](https://shizune.co/investors/profile/sv-angel) — VC Fund
- [Scott Banister](https://shizune.co/investors/profile/scott-banister) — Angel Investor
- [Accel](https://shizune.co/investors/profile/accel) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [OurCrowd](https://shizune.co/investors/profile/ourcrowd) — VC Fund
- [Entrée Capital](https://shizune.co/investors/profile/entree-capital) — VC Fund
- [Pitango VC](https://shizune.co/investors/profile/pitango-venture-capital) — VC Fund

## Featured in investor lists
- [All Angel Investors in Middle East](https://shizune.co/investors/angel-investors-middle-east)
- [All Angel Investors in Israel](https://shizune.co/investors/angel-investors-israel)
- [SaaS Angel Investors in Israel](https://shizune.co/investors/saas-angel-investors-israel)
- [Enterprise Angel Investors in Israel](https://shizune.co/investors/enterprise-angel-investors-israel)
- [Software Angel Investors in Middle East](https://shizune.co/investors/software-angel-investors-middle-east)
- [Health Care Investors in Middle East](https://shizune.co/investors/health-care-investors-middle-east)

## FAQ

### What does Marius Nacht invest in?

Marius Nacht invests primarily in Artificial Intelligence, Machine Learning and Health Care startups, most often at Series A and Series B stage. Most of the 34 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Marius Nacht's check size?

Marius Nacht typically joins rounds of $3M–$120M at Seed, $5M–$23M at Series A and $8M–$83M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Marius Nacht participates in.

### When did Marius Nacht last invest?

The most recent investment recorded for Marius Nacht closed in Sep 2024. Shizune tracks 34 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co